AIM ImmunoTech Inc.(AIM)Earnings, Financials & Key Ratios
AIM•AMEX
$0.56
$31M mkt cap·Price updated May 7, 2026
AboutAIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Show more
- Revenue$170K-15.8%
- EBITDA-$20M+38.4%
- Net Income-$17M+40.2%
- EPS (Diluted)-0.31+48.3%
- Gross Margin81.76%+3.2%
- EBITDA Margin-11485.88%+26.8%
- Operating Margin-11630.59%+26.4%
- Net Margin-10188.24%+28.9%
- ROE-388.69%-226.8%
- ROIC-546.09%-102.6%
- Interest Coverage-33.80
AIM Key Insights
AIM ImmunoTech Inc. (AIM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Shares diluted 15.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AIM Price & Volume
AIM ImmunoTech Inc. (AIM) stock price & volume — 10-year historical chart
Loading chart...
AIM Growth Metrics
AIM ImmunoTech Inc. (AIM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-1.46%
5 Years3.96%
3 Years7.99%
TTM-41.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM34.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1027.58%
Return on Capital
10 Years-105.37%
5 Years-123.79%
3 Years-190.97%
Last Year-403.43%
AIM Peer Comparison
AIM ImmunoTech Inc. (AIM) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMMP | 63.65M | 0.43 | -1.42 | 31.28% | -11.72% | -72.51% | 0.01 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 IOVA | 1.27B | 3.55 | -3.26 | 60.6% | -123.9% | -50.17% | 0.07 | |
 INO | 642.34M | 1.37 | -0.76 | -100% | -14.06% | 0.39 | ||
 NVAX | 1.5B | 9.23 | 3.63 | 64.69% | -14.73% | |||
 ADMA | 2.03B | 8.47 | 14.12 | 19.63% | 32.43% | 38.97% | 0.17 | |
 VXRT | 177.97M | 0.74 | 10.57 | 7.27% | 6.88% | 33.83% | 0.10 | |
 REGN | 73.68B | 709.10 | 17.10 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare AIM vs Peers
AIM ImmunoTech Inc. (AIM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AIM Income Statement
AIM ImmunoTech Inc. (AIM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 92K | 437K | 367K | 140K | 163K | 135K | 141K | 202K | 170K | 112K |
| Revenue Growth % | -30.83% | 375% | -16.02% | -61.85% | 16.43% | -17.18% | 4.44% | 43.26% | -15.84% | -41.05% |
| Cost of Goods Sold | 1.11M | 1.18M | 884K | 893K | 806K | 850K | -424K | 42K | 31K | 91K |
| COGS % of Revenue | 1204.35% | 270.71% | 240.87% | 637.86% | 494.48% | 629.63% | -300.71% | 20.79% | 18.24% | - |
| Gross Profit | -1.02M▲ 0% | -746K▲ 26.6% | -517K▲ 30.7% | -753K▼ 45.6% | -643K▲ 14.6% | -715K▼ 11.2% | 565K▲ 179.0% | 160K▼ 71.7% | 139K▼ 13.1% | 21K▲ 0% |
| Gross Margin % | -1104.35% | -170.71% | -140.87% | -537.86% | -394.48% | -529.63% | 400.71% | 79.21% | 81.76% | 18.75% |
| Gross Profit Growth % | 30.65% | 26.57% | 30.7% | -45.65% | 14.61% | -11.2% | 179.02% | -71.68% | -13.13% | - |
| Operating Expenses | 12.79M | 10.67M | 10.98M | 11.69M | 14.51M | 18.12M | 20.49M | 32.08M | 19.91M | 14.51M |
| OpEx % of Revenue | 13900% | 2441.65% | 2991.55% | 8350% | 8901.23% | 13424.44% | 14530.36% | 15879.21% | 11712.35% | - |
| Selling, General & Admin | 7.68M | 6.57M | 6.2M | 7.04M | 8.65M | 8.67M | 13.5M | 21.14M | 13.71M | 10.12M |
| SG&A % of Revenue | 8348.91% | 1503.89% | 1689.65% | 5027.86% | 5309.2% | 6423.7% | 9573.05% | 10463.86% | 8067.06% | - |
| Research & Development | 5.11M | 4.1M | 4.78M | 4.65M | 5.72M | 7.67M | 6.99M | 10.93M | 6.2M | 4.53M |
| R&D % of Revenue | 5551.09% | 937.76% | 1301.91% | 3322.14% | 3509.2% | 5682.96% | 4957.31% | 5408.42% | 3645.29% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 135K | 1.78M | 0 | 0 | 0 | -136K |
| Operating Income | -13.8M▲ 0% | -11.42M▲ 17.3% | -11.5M▼ 0.7% | -12.44M▼ 8.2% | -15.15M▼ 21.8% | -18.84M▼ 24.3% | -19.92M▼ 5.8% | -31.92M▼ 60.2% | -19.77M▲ 38.0% | -14.48M▲ 0% |
| Operating Margin % | -15004.35% | -2612.36% | -3132.43% | -8887.86% | -9295.71% | -13954.07% | -14129.65% | -15800% | -11630.59% | -12933.04% |
| Operating Income Growth % | 17.09% | 17.3% | -0.7% | -8.24% | -21.77% | -24.33% | -5.76% | -60.2% | 38.05% | - |
| EBITDA | -12.63M | -10.41M | -10.58M | -11.61M | -14.42M | -18.06M | -20.35M | -31.68M | -19.53M | -14.19M |
| EBITDA Margin % | -13733.7% | -2382.61% | -2881.74% | -8295.71% | -8846.01% | -13380% | -14430.36% | -15682.18% | -11485.88% | -12669.64% |
| EBITDA Growth % | 18.27% | 17.59% | -1.58% | -9.81% | -24.15% | -25.27% | -12.64% | -55.69% | 38.36% | 48.74% |
| D&A (Non-Cash Add-back) | 1.17M | 1M | 920K | 829K | 733K | 775K | -424K | 238K | 246K | 295K |
| EBIT | -7.5M | -8.12M | -9.32M | -8.98M | -13.73M | -19.06M | -19.45M | -28.96M | -16.73M | -15.2M |
| Net Interest Income | 129K | -51K | -470K | -338K | -453K | -67K | 629K | 0 | 4.61M | 4.33M |
| Interest Income | 129K | 88K | 32K | 89K | 219K | 0 | 629K | 0 | 5.19M | 4.89M |
| Interest Expense | 0 | 139K | 502K | 427K | 672K | 67K | 0 | 0 | 585K | 553K |
| Other Income/Expense | 6.3M | 3.16M | 1.67M | 3.04M | 752K | -289K | 477.81K | 2.95M | 2.45M | -1.26M |
| Pretax Income | -7.5M▲ 0% | -8.26M▼ 10.1% | -9.81M▼ 18.8% | -9.53M▲ 2.9% | -14.4M▼ 51.1% | -19.13M▼ 32.8% | -19.45M▼ 1.7% | -28.96M▼ 48.9% | -17.32M▲ 40.2% | -15.75M▲ 0% |
| Pretax Margin % | -8154.35% | -1889.93% | -2673.84% | -6809.29% | -8834.36% | -14168.15% | -13790.78% | -14337.62% | -10188.24% | -14062.5% |
| Income Tax | 0 | 0 | 2.19M | 1.29M | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | -22.27% | -13.56% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.5M▲ 0% | -8.26M▼ 10.1% | -9.81M▼ 18.8% | -10.83M▼ 10.3% | -14.4M▼ 33.0% | -19.13M▼ 32.8% | -19.45M▼ 1.7% | -28.96M▼ 48.9% | -17.32M▲ 40.2% | -15.75M▲ 0% |
| Net Margin % | -8154.35% | -1889.93% | -2673.84% | -7732.86% | -8834.36% | -14168.15% | -13790.78% | -14337.62% | -10188.24% | -14062.5% |
| Net Income Growth % | 50.74% | -10.09% | -18.82% | -10.32% | -33.01% | -32.83% | -1.66% | -48.94% | 40.2% | 34.18% |
| Net Income (Continuing) | -7.5M | -8.26M | -9.83M | -9.4M | -14.4M | -19.13M | -19.45M | -28.96M | -17.32M | -15.75M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -15.13▲ 0% | -12.67▲ 16.3% | -9.77▲ 22.9% | -2.97▲ 69.6% | -0.51▲ 82.8% | -0.45▲ 11.8% | -0.44▲ 2.2% | -0.60▼ 36.4% | -0.31▲ 48.3% | -7.52▲ 0% |
| EPS Growth % | 55.57% | 16.26% | 22.89% | 69.6% | 82.83% | 11.76% | 2.22% | -36.36% | 48.33% | -1027.58% |
| EPS (Basic) | -15.13 | -12.67 | -9.77 | -2.97 | -0.51 | -0.45 | -0.44 | -0.60 | -0.31 | - |
| Diluted Shares Outstanding | 495.86K | 651.72K | 1M | 3.64M | 31.84M | 47.34M | 48.05M | 48.59M | 56.02M | 2.09M |
| Basic Shares Outstanding | 495.86K | 651.72K | 1M | 3.64M | 31.84M | 47.34M | 48.05M | 48.59M | 56.02M | 2.09M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AIM Balance Sheet
AIM ImmunoTech Inc. (AIM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 6.94M | 3.5M | 3.8M | 10.45M | 40.31M | 50.21M | 36.32M | 14.56M | 4.18M | 2.58M |
| Cash & Short-Term Investments | 5.87M | 2.11M | 1.82M | 8.78M | 39M | 48.27M | 34.19M | 13.07M | 3.98M | 2.41M |
| Cash Only | 2.41M | 1.41M | 299K | 1.47M | 38.5M | 32.09M | 27.05M | 5.44M | 1.7M | 2.35M |
| Short-Term Investments | 3.46M | 695K | 1.53M | 7.31M | 501K | 16.18M | 7.14M | 7.63M | 2.28M | 62K |
| Accounts Receivable | 0 | 24K | 1.09M | 820K | 1.12M | 1.64M | 1.68M | 1.18M | 0 | 0 |
| Days Sales Outstanding | - | 20.05 | 1.09K | 2.14K | 2.52K | 4.44K | 4.34K | 2.14K | - | 15.48 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -302K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 764K | 764K | 0 | 0 | 184K | 0 | 455K | 302K | 199K | 166K |
| Total Non-Current Assets | 11.93M | 10.7M | 10.05M | 9.77M | 70.71M | 7.49M | 4.17M | 4.83M | 4.43M | 2.92M |
| Property, Plant & Equipment | 9.51M | 8.59M | 7.78M | 7.27M | 6.65M | 4.2M | 1.02M | 824K | 726K | 516K |
| Fixed Asset Turnover | 0.01x | 0.05x | 0.05x | 0.02x | 0.02x | 0.03x | 0.14x | 0.25x | 0.23x | 0.18x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 872K | 858K | 912K | 1.15M | 1.5M | 1.97M | 1.94M | 2.31M | 2.59M | 2.04M |
| Long-Term Investments | 0 | 0 | -40.29M | -45.09M | 15.38M | -25.02M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.55M | 1.26M | 1.35M | 1.35M | 116K | 1.32M | 1.2M | 1.69M | 1.11M | 2.57M |
| Total Assets | 18.87M▲ 0% | 14.21M▼ 24.7% | 13.85M▼ 2.5% | 20.22M▲ 46.0% | 111.02M▲ 449.1% | 57.7M▼ 48.0% | 40.49M▼ 29.8% | 19.38M▼ 52.1% | 8.61M▼ 55.6% | 5.49M▲ 0% |
| Asset Turnover | 0.00x | 0.03x | 0.03x | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.02x | 0.02x |
| Asset Growth % | -17.24% | -24.72% | -2.55% | 46.04% | 449.09% | -48.03% | -29.83% | -52.13% | -55.59% | -250.28% |
| Total Current Liabilities | 2.44M | 2.71M | 5.29M | 1.13M | 1.1M | 673K | 1.36M | 8.65M | 9.54M | 4.04M |
| Accounts Payable | 887K | 741K | 680K | 472K | 383K | 198K | 377K | 6.44M | 6.38M | 1.25M |
| Days Payables Outstanding | 292.2 | 228.63 | 280.77 | 192.92 | 173.44 | 85.02 | -324.54 | 55.99K | 75.15K | 21.94K |
| Short-Term Debt | 0 | 0 | 3.61M | 214K | 277K | 0 | 0 | 0 | 2.31M | 2.11M |
| Deferred Revenue (Current) | 0 | 0 | 806K | 189K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 309K | 440K | 0 | 1K | 1.57M | 1K | 662K |
| Current Ratio | 2.85x | 1.29x | 0.72x | 9.27x | 36.58x | 74.61x | 26.69x | 1.68x | 0.44x | 0.44x |
| Quick Ratio | 2.85x | 1.29x | 0.72x | 9.27x | 36.58x | 74.61x | 26.69x | 1.72x | 0.44x | 0.44x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -21.92K |
| Total Non-Current Liabilities | 940K | 2.8M | 3.38M | 6.18M | 48.63M | 147K | 659K | 495K | 395K | 7.53M |
| Long-Term Debt | 0 | 1.83M | 0 | 3.91M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 2.32M | 2.22M | 2.01M | 112K | 659K | 495K | 395K | 1.24M |
| Deferred Tax Liabilities | 0 | 0 | 40.29M | 44.56M | 46.44M | 23.71M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 940K | 962K | 1.06M | 57K | 180K | 35K | 0 | 0 | 0 | 7.3M |
| Total Liabilities | 3.38M | 5.5M | 8.67M | 7.31M | 49.73M | 820K | 2.02M | 9.15M | 9.93M | 11.57M |
| Total Debt | 0 | 1.83M | 5.92M | 6.38M | 2.29M | 149K | 837K | 718K | 2.94M | 2.34M |
| Net Debt | -2.41M | 423K | 5.63M | 4.91M | -36.22M | -31.94M | -26.22M | -4.72M | 1.24M | -9K |
| Debt / Equity | - | 0.21x | 1.15x | 0.49x | 0.04x | 0.00x | 0.02x | 0.07x | - | -0.38x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.16x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.00x |
| Interest Coverage | - | -82.13x | -22.90x | -29.14x | -22.55x | -281.16x | - | - | -33.80x | -27.48x |
| Total Equity | 15.5M▲ 0% | 8.7M▼ 43.8% | 5.17M▼ 40.5% | 12.91M▲ 149.5% | 61.29M▲ 374.9% | 56.88M▼ 7.2% | 38.47M▼ 32.4% | 10.23M▼ 73.4% | -1.32M▼ 112.9% | -6.08M▲ 0% |
| Equity Growth % | -23.92% | -43.84% | -40.55% | 149.46% | 374.89% | -7.2% | -32.37% | -73.4% | -112.92% | -808.8% |
| Book Value per Share | 31.25 | 13.35 | 5.15 | 3.54 | 1.92 | 1.20 | 0.80 | 0.21 | -0.02 | -2.90 |
| Total Shareholders' Equity | 15.5M | 8.7M | 5.17M | 12.91M | 61.29M | 56.88M | 38.47M | 10.23M | -1.32M | -6.08M |
| Common Stock | 24K | 33K | 49K | 10K | 42K | 48K | 48K | 49K | 66K | 3K |
| Retained Earnings | -300.5M | -308.76M | -318.57M | -328.11M | -341.97M | -361.1M | -380.55M | -409.51M | -426.83M | -436.61M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5K | 11K | -3K | 0 | -47K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AIM Cash Flow Statement
AIM ImmunoTech Inc. (AIM) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.38M | -7.94M | -10.64M | -9.07M | -10.37M | -13.96M | -16.11M | -21.27M | -14.89M | -14.89M |
| Operating CF Margin % | -8021.74% | -1817.16% | -2899.18% | -6476.43% | -6360.74% | -10344.44% | -11424.11% | -10528.22% | -8757.65% | - |
| Operating CF Growth % | 54.03% | -7.6% | -33.99% | 14.78% | -14.35% | -34.69% | -15.35% | -32.03% | 29.99% | 96.23% |
| Net Income | -7.5M | -8.26M | -9.81M | -9.53M | -14.4M | -19.13M | -19.45M | -28.96M | -17.32M | -15.75M |
| Depreciation & Amortization | 1.3M | 1.01M | 878K | 792K | 733K | 805K | 256K | 238K | 246K | 231K |
| Stock-Based Compensation | 410K | 571K | 929K | 853K | 1.04M | 1.57M | 954K | 243K | 686K | 256K |
| Deferred Taxes | 57K | -17K | -1.4M | -891K | -96K | -2.32M | 197K | 5.84M | 0 | 0 |
| Other Non-Cash Items | -1.68M | -2.38M | 845K | 255K | 1.75M | 4.24M | 964K | 310K | 1.2M | 1.68M |
| Working Capital Changes | 29K | 1.13M | -2.08M | -543K | 605K | 895K | 966K | 1.06M | 296K | 662K |
| Change in Receivables | 0 | -24K | -1.07M | 274K | 40K | 34K | -35K | 492K | 1.18M | 3K |
| Change in Inventory | -1.33M | 0 | 0 | -647K | 0 | 0 | 35K | 0 | 0 | 0 |
| Change in Payables | -326K | 566K | 166K | -207K | -89K | -185K | 179K | 0 | -60K | -1.54M |
| Cash from Investing | 2.92M | 2.73M | 92K | -6.15M | -9.16M | -631K | 10.99M | -832K | 4.71M | 5.65M |
| Capital Expenditures | -454K | -69K | -127K | -365K | -595K | -633K | -271K | -585K | -18K | -402K |
| CapEx % of Revenue | 493.48% | 15.79% | 34.6% | 260.71% | 365.03% | 468.89% | 192.2% | 289.6% | 10.59% | - |
| Acquisitions | 0 | 0 | 755K | 0 | 573K | 592K | 3.9M | 47K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 1.13M | 0 | -573K | -347K | 0 | 0 | -631K | 0 |
| Cash from Financing | 4.76M | 4.21M | 9.44M | 16.39M | 56.56M | 8.19M | 80K | 485K | 6.44M | 8.71M |
| Debt Issued (Net) | -1K | 1.9M | 4.92M | 1.08M | -4.68M | -4.85M | 0 | 0 | 2.25M | 5M |
| Equity Issued (Net) | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 80K | 485K | 892K | 399K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 4.76M | -102K | 4.52M | 0 | 0 | 0 | 0 | 0 | 3.3M | 3.3M |
| Net Change in Cash | 293K▲ 0% | -996K▼ 439.9% | -1.11M▼ 11.7% | 1.17M▲ 205.2% | 37.03M▲ 3062.3% | -6.41M▼ 117.3% | -5.04M▲ 21.3% | -21.61M▼ 328.8% | -3.74M▲ 82.7% | 1.43M▲ 0% |
| Free Cash Flow | -7.83M▲ 0% | -8.01M▼ 2.2% | -10.77M▼ 34.4% | -9.43M▲ 12.4% | -10.96M▼ 16.2% | -14.6M▼ 33.2% | -16.38M▼ 12.2% | -21.85M▼ 33.4% | -14.91M▲ 31.8% | -13.33M▲ 0% |
| FCF Margin % | -8515.22% | -1832.95% | -2933.79% | -6737.14% | -6725.77% | -10813.33% | -11616.31% | -10817.82% | -8768.24% | -11900% |
| FCF Growth % | 52.64% | -2.25% | -34.42% | 12.4% | -16.23% | -33.16% | -12.2% | -33.41% | 31.79% | 37.5% |
| FCF per Share | -15.80 | -12.29 | -10.72 | -2.59 | -0.34 | -0.31 | -0.34 | -0.45 | -0.27 | -0.27 |
| FCF Conversion (FCF/Net Income) | 0.98x | 0.96x | 1.08x | 0.84x | 0.72x | 0.73x | 0.83x | 0.73x | 0.86x | 0.85x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AIM Key Ratios
AIM ImmunoTech Inc. (AIM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -41.83% | -68.25% | -141.43% | -119.75% | -38.81% | -32.37% | -40.79% | -118.94% | -388.69% | 353.89% |
| Return on Invested Capital (ROIC) | -66.05% | -77.08% | -86.54% | -65.22% | -52.99% | -56.5% | -80.36% | -269.48% | -546.09% | -546.09% |
| Gross Margin | -1104.35% | -170.71% | -140.87% | -537.86% | -394.48% | -529.63% | 400.71% | 79.21% | 81.76% | 18.75% |
| Net Margin | -8154.35% | -1889.93% | -2673.84% | -7732.86% | -8834.36% | -14168.15% | -13790.78% | -14337.62% | -10188.24% | -14062.5% |
| Debt / Equity | - | 0.21x | 1.15x | 0.49x | 0.04x | 0.00x | 0.02x | 0.07x | - | -0.38x |
| Interest Coverage | - | -82.13x | -22.90x | -29.14x | -22.55x | -281.16x | - | - | -33.80x | -27.48x |
| FCF Conversion | 0.98x | 0.96x | 1.08x | 0.84x | 0.72x | 0.73x | 0.83x | 0.73x | 0.86x | 0.85x |
| Revenue Growth | -30.83% | 375% | -16.02% | -61.85% | 16.43% | -17.18% | 4.44% | 43.26% | -15.84% | -41.05% |
AIM Frequently Asked Questions
AIM ImmunoTech Inc. (AIM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AIM ImmunoTech Inc. (AIM) reported $0.1M in revenue for fiscal year 2024. This represents a 96% decrease from $3.0M in 1995.
AIM ImmunoTech Inc. (AIM) saw revenue decline by 15.8% over the past year.
AIM ImmunoTech Inc. (AIM) reported a net loss of $15.8M for fiscal year 2024.
Dividend & Returns
AIM ImmunoTech Inc. (AIM) has a return on equity (ROE) of -388.7%. Negative ROE indicates the company is unprofitable.
AIM ImmunoTech Inc. (AIM) had negative free cash flow of $13.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More AIM
AIM ImmunoTech Inc. (AIM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates